<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Autoantibodies (Ab's) to the "B" <z:chebi fb="7" ids="16670">peptide</z:chebi> (amino acids 372-395) of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>/AMPA receptor subtype 3 (GluR3) are found in serum and cerebrospinal fluid of some patients with different types of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Since such anti-GluR3B Ab's can activate and/or kill neurons in vitro and in vivo, they may contribute to <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate whether anti-GluR3B Ab's may also be relevant to <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> when it accompanies some <z:hpo ids='HP_0002960'>autoimmune-diseases</z:hpo>, we tested for these Ab's in patients suffering from <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> that accompanies anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (APS) or <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon's syndrome</z:e> (SNS), both being <z:hpo ids='HP_0002960'>autoimmune-diseases</z:hpo> with frequent neurological complications </plain></SENT>
<SENT sid="3" pm="."><plain>We tested 77 pediatric patients whose <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> is their main disease; 31 adult patients whose <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> accompanies APS (primary or SLE-associated) or SNS; 45 epilepsy-free APS and SNS patients; and 90 healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain>Compared to the controls, significantly elevated anti-GluR3B Ab's were found in 22/77 (29%) patients whose <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> is their main disease, but in none of the patients whose <z:hpo ids='HP_0001250'>seizures</z:hpo> accompany APS or SNS </plain></SENT>
<SENT sid="5" pm="."><plain>Yet, <z:hpo ids='HP_0000001'>all</z:hpo> the APS and SNS patients harbored the characteristic anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> Ab's (aPL), directed against <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> and beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I, and had <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> anti-coagulant </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, anti-GluR3B Ab's are not crossreactive with aPL, and not produced as a non-specific consequence of <z:hpo ids='HP_0001250'>seizures</z:hpo> on the one hand, or <z:hpo ids='HP_0002960'>autoimmune-diseases</z:hpo> on the other </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together with new findings accumulated recently in our lab, we suggest that anti-GluR3B Ab's are produced primarily in the periphery due to specific/non-specific "irritation" of the immune system, and that once they reach the brain via a leaky blood-brain barrier they may cause neuronal/glial damage and facilitate the outburst of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> and additional <z:hpo ids='HP_0000707'>neurological abnormalities</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, the presence of anti-GluR3B Ab's does not seem to increase the probability of developing APS, SNS or the <z:hpo ids='HP_0001250'>seizures</z:hpo> that often accompany these <z:hpo ids='HP_0002960'>autoimmune-diseases</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>These findings may have important diagnostic and therapeutic implications </plain></SENT>
</text></document>